Abbott has announced its acquisition of Exact Sciences, a move that will propel Abbott into the fast-growing cancer screening and precision oncology diagnostics segments. The acquisition is valued at approximately $21 billion and is expected to be immediately accretive to Abbott's revenue growth and gross margin.
Exact Sciences is projected to generate more than $3 billion in revenue this year, with a high teens organic sales growth rate. Once the transaction is completed, Exact Sciences will become a subsidiary of Abbott, and Abbott’s total diagnostics sales will exceed $12 billion annually.
Exact Sciences offers a range of products, including the market-leading Cologuard® and Oncotype DX® tests, as well as cutting-edge liquid biopsy tests for multi-cancer early detection and molecular residual disease testing. The company focuses on the early detection of cancer and supporting personalized treatments, with offerings such as the Cancerguard™ test for multi-cancer early detection and the Oncodetect™ test for molecular residual disease and recurrence monitoring.
Following the acquisition, Exact Sciences will maintain its presence in Madison, Wisconsin, and Kevin Conroy, the chairman and chief executive officer of Exact Sciences, will remain with the company in an advisory role to support the transition into Abbott.
The acquisition will enable Abbott to expand its access to life-changing diagnostics and help more people detect and manage cancer at its earliest, most treatable stages. Abbott's total diagnostics sales are expected to exceed $12 billion annually once the transaction is completed, positioning the company as a leader in the fast-growing cancer diagnostics segments.
The closing of the acquisition is expected in the second quarter of 2026 and is subject to Exact Sciences’ shareholder approval, as well as receipt of applicable regulatory approvals and other customary closing conditions.
This acquisition represents a significant strategic move for Abbott, as it aims to transform cancer care, advance earlier detection, and optimize treatment and monitoring to help millions more people live healthier lives. As a result of these announcements, the company's shares have moved -1.18% on the market, and are now trading at a price of $124.66. For more information, read the company's full 8-K submission here.
